INSM
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated (INSM) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (A+); its weakest is Revisions (F). The rating has held at C for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-12 | D (1.5) | A+ (4.6) | B (3.4) | C (2.4) | F (0.0) | C (2.4) |
| 2026-11-05 | D (1.5) | A+ (4.6) | B (3.4) | C- (2.1) | F (0.0) | C (2.3) |
| 2026-10-29 | D+ (1.6) | A+ (4.6) | B (3.4) | C (2.4) | F (0.0) | C (2.4) |
| 2026-10-22 | D+ (1.6) | A+ (4.6) | B (3.4) | C (2.2) | F (0.0) | C (2.4) |
| 2026-10-15 | D+ (1.6) | A+ (4.6) | B (3.4) | C (2.3) | F (0.0) | C (2.4) |